Orexo
18,98
SEK
-3,26 %
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Mindre end 1K følgere
-3,26%
+8,46%
+6,63%
+74,77%
+15,45%
+35,77%
-39,71%
-72,25%
-78,9%
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Læs mereMarkedsværdi
658,81 mio. SEK
Aktieomsætning
384,96 t SEK
Omsætning
638,8 mio.
EBIT %
-17,14 %
P/E
-
Udbytteafkast, %
-
Finanskalender
6.2
2025
Årsrapport '24
6.5
2025
Delårsrapport Q1'25
8.5
2025
Generalforsamling '25
ViserAlle indholdstyper
Orexo converts future rights for OX-MPI to shares in Gesynta Pharma valued at SEK 19 million
Carnegie Access: Orexo: Positive OX640 read-out
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools